COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00377975
Recruitment Status : Completed
First Posted : September 19, 2006
Last Update Posted : January 25, 2016
Information provided by (Responsible Party):
Steven Smith, Pennington Biomedical Research Center

Brief Summary:
This study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. The four treatments are: Placebo, Ephedrine plus caffeine, Pioglitazone, Combined pioglitazone and ephedrine plus caffeine

Condition or disease Intervention/treatment Phase
Obesity Drug: Ephedrine Drug: Pioglitazone Drug: Caffeine Phase 2

Detailed Description:
The sympathetic nervous system, via the intracellular messenger cAMP and MAPK activation, and thiazolidinediones via PPARγ control lipid metabolism have been implicated in body weight regulation. The present study was undertaken to determine whether the simultaneous activation of these two signaling systems might synergize to exert beneficial effects on the expression of key genes involved in lipid metabolism and mitochondrial biogenesis in subcutaneous fat in healthy, non-diabetic subjects. Fifty seven non-diabetic women and men were randomized into four groups: 1) placebo/placebo (PP); 2) ephedrine plus caffeine/placebo (ECP); 3) placebo/pioglitazone (PPio); 4) ephedrine plus caffeine/pioglitazone (ECPio). Adipose tissue samples were obtained after 12 weeks of treatment to determine gene expression by real time RT-PCR.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Synergistic Induction of UCP-1 by Ephedrine/Caffeine and Pioglitazone: A Rationale for Combination Therapy of Obesity
Study Start Date : January 2003
Study Completion Date : November 2004

Primary Outcome Measures :
  1. Percent fat after 16 weeks treatment using a Hologic QDR 4500 DEXA.

Secondary Outcome Measures :
  1. UCP-1 gene expression by quantitative RT-PCR
  2. fat mass, lean mass
  3. visceral adiposity by multi-slice CT scanning
  4. resting metabolic rate and thermic effect of a single dose of ephedrine and caffeine
  5. adipose tissue gene expression profiling using oligonucleotide array

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • generally healthy
  • not pregnant or nursing
  • using adequate contraception
  • between 18 and 50 years of age
  • BMI between 30 and 35 kg/m2

Exclusion Criteria:

  • significant renal, cardiac, liver, lung or neurological disease
  • high blood pressure
  • diabetes
  • prior use of thiazolidinedione
  • prior use of beta-blockers alcohol or drug abuse
  • history of thrombophlebitis, vascular or blood clotting disorders
  • unwilling or unable to abstain from caffeinated beverages and alcohol prior to adipose tissue biopsy and metabolic rates measurements
  • increased liver function test at baseline
  • have metal objects that would interfere with the measurement of the body composition
  • use drugs known to affect lipid metabolism, energy metabolism or body weight
  • use herbal supplements containing ephedrine and/or caffeine
  • take chronic medication, except hormone replacement or contraception
  • are a woman unwilling to use effective contraception during the trial
  • have heart disease or history of stroke
  • have urinary symptoms from enlarged prostate
  • have gained and or lost more than 10 pounds in the last 6 month
  • have use a monoamine oxidase inhibitor medication in the last month
  • have high or low thyroid function that has not been controlled in the normal range for at least 2 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00377975

Layout table for location information
United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808
Sponsors and Collaborators
Pennington Biomedical Research Center
Layout table for investigator information
Principal Investigator: Steven R Smith, M.D. Pennington Biomedical Research Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Steven Smith, Associate Professor, Adjunct, Pennington Biomedical Research Center Identifier: NCT00377975    
Other Study ID Numbers: PBRC 22021
First Posted: September 19, 2006    Key Record Dates
Last Update Posted: January 25, 2016
Last Verified: January 2016
Keywords provided by Steven Smith, Pennington Biomedical Research Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight
Hypoglycemic Agents
Physiological Effects of Drugs
Central Nervous System Stimulants
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Adrenergic Agents